ADC Therapeutics SA (NYSE:ADCT)
$ 2.93 -0.05 (-1.68%) Market Cap: 283.30 Mil Enterprise Value: 112.41 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 46/100

ADC Therapeutics SA at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2022 / 03:45PM GMT
Release Date Price: $5.7 (-5.00%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Good morning, afternoon. It's still morning, right? Good morning, everybody, almost afternoon. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Really pleased to have ADC Therapeutics with us for the next session.

Quickly before we get started, I just need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures. So with that, pleased to have Ameet Mallik, who's the CEO at ADC.

Questions & Answers

Matthew Kelsey Harrison;Ameet Mallik<
Morgan Stanley, Research Division - Executive Director

Maybe just a nice place to start is you joined a couple of months ago, I guess, at this point. Maybe just talk to us about why you joined? Why you think it's an interesting opportunity and what you're looking forward to?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot